ONO Pharmaceutical, a pharmaceutical company in Japan, offered to merge with Deciphera Pharmaceuticals, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, in a $2.4bn deal. “Deciphera and ONO share a deep commitment to improve the lives of people living with cancer, and the transaction announced today enables us to make even greater impact for patients. Together, we expect to advance and accelerate each organization’s important work through combined research and development capabilities and a global commercial footprint. Importantly, this acquisition delivers for all of Deciphera’s stakeholders. It provides immediate, compelling value for our shareholders, provides greater opportunities for our world-class team, and ultimately, greater hope for patients. I am excited about the future of the combined organization, and we are honored to contribute to the continued growth of ONO in the U.S. and around the world," Steven L. Hoerter, Deciphera Pharmaceuticals President and CEO.